NDAINTRAVENOUSPOWDER
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
AXTLE (pemetrexed) by Viatris (2) is folic acid metabolism inhibitors [moa]. Approved for non-small cell lung cancer. First approved in 2024.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AXTLE (pemetrexed) is a folic acid metabolism inhibitor administered intravenously as a powder for injection. It is indicated for non-small cell lung cancer (NSCLC) and works by disrupting folate-dependent metabolic pathways essential for DNA synthesis and cell division. This mechanism makes it suitable for combination or maintenance therapy in advanced lung cancer.
Growth
Early-stage growth product with moderate competitive pressure (30%) presents opportunity for brand building and market establishment on a lean, agile team.
Mechanism of Action
Folic Acid Metabolism Inhibitors
Pharmacologic Class:
Folate Analog Metabolic Inhibitor
Indications (1)
Clinical Trials (20)
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
Started Jun 2027
16 enrolled
Lung Non-Squamous Non-Small Cell Carcinoma
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Started Nov 2025
596 enrolled
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Started Oct 2025
600 enrolled
Non-Small Cell Lung CancerKRAS G12C Lung Cancer
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Started Dec 2024
19 enrolled
Lung Cancer (NSCLC)Leptomeningeal Metastasis
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Started Jun 2024
520 enrolled
Non-small Cell Lung Cancer (NSCLC)
Worked on AXTLE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.